Vericel (VCEL) Acquisitions (2014 - 2019)
Vericel (VCEL) posted Acquisitions of $13.9 million for Q3 2019, down 35.99% sequentially from $21.7 million in Q2 2019, and down 68.75% YoY from $44.5 million in Q3 2018.
Analysis
Vericel (VCEL) Acquisitions (2014 - 2019) Analysis & Trends
Vericel has reported Acquisitions for 6 years, with the latest figure at $13.9 million in Q3 2019.
- Quarterly Acquisitions fell 68.75% year-over-year to $13.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $90.8 million (up 105.36% YoY) and the FY2014 annual result came in at $1.4 million, changed N/A from the prior year.
- Acquisitions declined to $13.9 million in Q3 2019 per VCEL's latest filing, from $21.7 million in the prior quarter.
- Over five years, Acquisitions peaked at $44.5 million in Q3 2018 and troughed at -$2.3 million in Q4 2015.
- A 5-year average of $6.1 million and a median of $353000.0 in 2015 frame the typical range for Acquisitions.
- The sharpest annual moves came in 2017 and 2018: Acquisitions tumbled 213.75% in 2017, then jumped 16393.04% in 2018.
- Over 5 years, Acquisitions stood at -$2.3 million in 2015, then soared by 43.61% to -$1.3 million in 2016, then soared by 79.22% to -$273000.0 in 2017, then surged by 16393.04% to $44.5 million in 2018, then sank by 68.75% to $13.9 million in 2019.
- According to Business Quant data, Acquisitions over the past three periods registered $13.9 million, $21.7 million, and $10.7 million for Q3 2019, Q2 2019, and Q1 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 13.90 Mn |
| Jun 30, 2019 | 21.72 Mn |
| Mar 31, 2019 | 10.69 Mn |
| Sep 30, 2018 | 44.48 Mn |
| Sep 30, 2017 | -273,000.00 |
| Jun 30, 2017 | 203,000.00 |
| Mar 31, 2017 | 70,000.00 |
| Dec 31, 2016 | -1.31 Mn |
| Sep 30, 2016 | 240,000.00 |
| Jun 30, 2016 | 1.06 Mn |
| Mar 31, 2016 | 13,000.00 |
| Dec 31, 2015 | -2.33 Mn |
| Sep 30, 2015 | 775,000.00 |
| Jun 30, 2015 | 1.20 Mn |
| Mar 31, 2015 | 353,000.00 |
| Sep 30, 2014 | 2.50 Mn |
| Jun 30, 2014 | -1.05 Mn |